2020
Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies
Jackson A, Grobman B, Krishnan-Sarin S. Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies. Neuropharmacology 2020, 176: 108218. PMID: 32592708, PMCID: PMC7529934, DOI: 10.1016/j.neuropharm.2020.108218.Peer-Reviewed Original ResearchConceptsE-cigarettesVivo studiesNicotine productsCentral nervous system implicationsNon-combustible nicotine productsNicotine e-cigarettesLung injury casesPharmacokinetics of nicotineE-liquidsHeated tobacco productsTobacco product usersSearch engines PubMedProduct use-associated lung injury (EVALI) casesPharmacodynamic impactNon-combustible productsNicotine inhalerNicotine studiesMouse modelRodent modelsNicotine pharmacologyRodent studiesInjury casesPG/VGPharmacological impactNarrative review
2013
Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study.
Cloughesy T, Mischel P, Omuro A, Prados M, Wen P, Wu B, Rockich K, Xu Y, Lager J, Mellinghoff I. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. Journal Of Clinical Oncology 2013, 31: 2012-2012. DOI: 10.1200/jco.2013.31.15_suppl.2012.Peer-Reviewed Original ResearchPan-PI3K inhibitorCohort 1Cohort 2Frozen tumor tissueTumor tissueTumor samplesK inhibitorsArchived tumor samplesPK/PD analysisPI3K/mTOR pathwayPD analysisTreatment of glioblastomaInhibition of proliferationPI3K inhibitorsPharmacodynamic impactEarly surgeryLast doseSurgical resectionCNS tumorsMean tumorRecurrent glioblastomaTumor resectionFFPE tumor samplesPK analysisCohort 3
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply